The microbial contract biomanufacturing market is growing at a CAGR of 8.7%, claims {Roots Analysis}

Technical advances, especially in the field of biotechnology, have led to the development of several next generation preventive vaccines, including recombinant vaccines, viral vector based vaccines and DNA vaccines, which have been demonstrated to elicit powerful immune responses, resulting in the development of immunological memory.

 

To order this 250+ page report, which features 85+ figures and 125+ tables, please visit this link

 

The USD 94 billion (by 2030) financial opportunity within the global preventive vaccine market has been analyzed across the following segments:

  • Route of Administration
  • Intramuscular
  • Subcutaneous
  • Oral
  • Intravenous
  • Others

 

  • Type of Vaccine
  • Pneumococcal Conjugate Vaccine
  • Human Papilloma Virus Vaccine
  • Rotavirus Vaccine
  • Influenza Vaccine
  • MMR Vaccine
  • Tetanus and Diphtheria Booster Vaccine
  • Varicella Vaccine
  • DTaP-Hib-IPV Vaccine
  • DTaP-HepB-Hib-IPV Vaccine
  • Others

 

  • Type of Vaccine API
  • Live, Attenuated Vaccine
  • Inactivated Vaccine
  • Conjugate Vaccine
  • Subunit Vaccine
  • Toxoid Vaccine
  • Others

 

  • Target Patient Population
  • Pediatric Patients
  • Adults

 

  • Key Players
  • GlaxoSmithKline
  • Merck
  • Sanofi Pasteur
  • Pfizer
  • Emergent BioSolutions
  • CSL
  • Others

 

  • Key Geographical Regions
  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

 

The Global Preventive Vaccines Market, 2020-2030 report features the following companies, which we identified to be key players in this domain:

  • Bio Farma
  • Emergent BioSolutions
  • GC Pharma
  • GlaxoSmithKline
  • Janssen
  • Merck
  • Novavax
  • Pfizer
  • Sanofi Pasteur
  • Valneva

 

Table of Contents

 

  1. Preface2. Executive Summary
  2. Introduction
  3. Market Landscape
  4. Company Competitiveness Analysis
  5. Company Profiles
  6. Clinical Trial Analysis
  7. Ongoing Vaccine Development Initiatives for Complex Conditions
  8. Funding and Investment Analysis
  9. Market Sizing and Opportunity Analysis
  10. Case-in-Point: Contract Manufacturing of Vaccines
  11. Concluding Remarks

 

  1. Executive Insights

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/preventive-vaccines/318.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com